Skip to main content Skip to main content
VitalDecades logo VitalDecades

Biomarker library / Lipids

LDL cholesterol (LDL-C)

Also called low-density lipoprotein cholesterol, "bad" cholesterol

The cholesterol carried in low-density lipoprotein particles, usually calculated from a standard lipid panel. LDL particles deposit cholesterol in artery walls, which is why LDL-C is the number most cholesterol treatment decisions are keyed to.

By , Longevity & Research Sources checked Corrected How pages are checked

01  /  Guideline numbers

What the guidelines say about this number

Save this result

Stored on your account and never shared. We are not sending email yet, so band-change alerts will not arrive until we turn sending on. Export or delete it any time from My numbers.

Population Adults (2026 ACC/AHA)
Category Severe hypercholesterolemia: maximally tolerated statin
Range 190 or higher mg/dL No risk calculation needed: ACC's September 1, 2026 feature lists LDL-C of 190 or higher as a statin indication without further risk assessment. Figure 7 first rules out secondary causes and calls for screening first-degree relatives.
Population Adults 30 to 79 without ASCVD, primary prevention (2026 ACC/AHA)
Category Statin decision by 10-year PREVENT-ASCVD risk
Range 70 to 189 mg/dL 10-year PREVENT-ASCVD risk: low under 3%, borderline 3% to under 5%, intermediate 5% to under 10%, high 10% or more.
Population Primary prevention, borderline or intermediate PREVENT-ASCVD risk (2026 ACC/AHA goal)
Category LDL-C goal
Range under 100 mg/dL Borderline is a 10-year PREVENT-ASCVD risk of 3% to under 5%; intermediate is 5% to under 10%. The guideline's Figures 1 and 6 also set this goal for a low-risk adult who starts a statin.
Population Primary prevention, high PREVENT-ASCVD risk of 10% or more (2026 ACC/AHA goal)
Category LDL-C goal
Range under 70 mg/dL
Population Clinical ASCVD at very high risk (2026 ACC/AHA goal)
Category LDL-C goal; add ezetimibe and/or a PCSK9 antibody if not reached
Range under 55 mg/dL With at least a 50% reduction and non-HDL-C under 85 mg/dL.

Normal vs optimal

Instead of a normal or optimal LDL-C, the 2026 guideline's goal figure sets goals by risk group: under 100 mg/dL in primary prevention below a 10-year PREVENT-ASCVD risk of 10% (the AHA's release names this group as borderline or intermediate risk); under 70 at high risk (a 10-year PREVENT-ASCVD risk of 10% or more); under 70 for clinical ASCVD that is not at very high risk; and under 55 for clinical ASCVD at very high risk. The guideline pairs each with a non-HDL cholesterol goal (under 130, 100, 100 and 85 mg/dL, in that order), and the under-70 and under-55 goals also call for at least a 50% LDL-C reduction. If your lab flags an LDL-C under 70 mg/dL as low, ACC's September 2026 feature says laboratories still doing so can be asked to drop that alert.

02  /  Why it matters

What the number tells you

One guideline now sets how LDL-C is read in the US: the 2026 ACC/AHA multisociety Guideline on the Management of Dyslipidemia, issued by 11 societies, among them the ACC, the AHA and the National Lipid Association, and published online March 13, 2026. It "retires and replaces" the 2018 cholesterol guideline. In the guideline material we could read, the one named LDL-C category is severe hypercholesterolemia, an LDL-C of 190 mg/dL or higher. Its algorithm for this group first rules out or addresses secondary causes and calls for screening first-degree relatives and completing genetic testing, then says "Initiate maximally tolerated statin". ACC's September 2026 feature on the guideline lists LDL-C of 190 or higher, alongside diabetes, as a statin indication that needs no further risk assessment.

Below 190, the number works through your risk. For adults 30 to 79 without atherosclerotic cardiovascular disease (ASCVD) whose LDL-C is 70 to 189 mg/dL, the guideline's primary-prevention algorithm says to "Calculate 10-y and 30-y ASCVD risk using PREVENT-ASCVD". The AHA groups 10-year PREVENT-ASCVD risk as low (under 3%), borderline (3% to under 5%), intermediate (5% to under 10%) and high (10% or more), and the guideline sets LDL-C goals by group. An LDL-C of 160 to 189 has two further roles: held there persistently, it is one of the guideline's risk enhancers, and at low 10-year risk it is one of two routes (the other is a 30-year risk of 10% or more) to considering a moderate-intensity statin. Two one-page corrections to the guideline were published on June 22 and September 8, 2026, and we could not read them, so the numbers here are as printed before them: the 190 line and the under-55 goal in ACC's reproduction of the guideline's figures, read October 19, 2026, and the other rows in the AHA's March 13, 2026 release.

03  /  In practice

Testing and what moves it

When it is tested

  • As part of a lipid panel. ACC's Learning Center summary of the 2026 guideline describes universal lipid screening for adults starting at age 19, every 5 years.
  • The USPSTF ties statin decisions to adults 40 to 75 with risk factors. Its August 23, 2022 recommendation: "The USPSTF recommends that clinicians prescribe a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD risk factors (i.e. dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10-year risk of a cardiovascular event of 10% or greater."
  • Very high triglycerides can distort a calculated LDL-C.

What raises it

  • Saturated and trans fat intake, genetics (familial hypercholesterolemia is the classic cause of LDL-C 190 or above), hypothyroidism, nephrotic syndrome, some medications.

What lowers it

  • Statins, ezetimibe, PCSK9 inhibitors and other lipid-lowering drugs; dietary change (less saturated fat, more soluble fiber); weight loss has a modest effect.

04  /  Related

Frequently asked questions

Is 130 mg/dL LDL high?

No current US guideline we found labels 130 mg/dL on its own. Under the 2026 ACC/AHA guideline, what it means depends on your 10-year PREVENT-ASCVD risk and on whether you have ASCVD: the goal is under 100 mg/dL below a 10-year PREVENT-ASCVD risk of 10%, under 70 at high risk or with clinical ASCVD that is not at very high risk, and under 55 for clinical ASCVD at very high risk. The "borderline high" label for 130 to 159 comes from the 2001 NCEP ATP III classification; NHLBI's own ATP III page notes that new ACC/AHA guidelines on the topic were published on November 12, 2013.

Why do some doctors want LDL under 70 or under 55?

Those are 2026 ACC/AHA goals for specific groups. Under 70 mg/dL is the goal in primary prevention at a 10-year PREVENT-ASCVD risk of 10% or more, and for clinical ASCVD that is not at very high risk. Under 55 is the goal for clinical ASCVD at very high risk, with at least a 50% reduction and a non-HDL cholesterol under 85; if it is not reached, the guideline's algorithm adds ezetimibe and/or a PCSK9 antibody. They are goals for those groups, not a reference range for every adult.

What does an LDL of 190 or higher mean?

The 2026 ACC/AHA guideline calls it severe hypercholesterolemia and covers the group in its Section 4.2.4. Its algorithm for these adults first rules out or addresses secondary causes and calls for screening first-degree relatives and completing genetic testing, then says "Initiate maximally tolerated statin". ACC lists an LDL-C of 190 or higher as a statin indication that needs no further risk assessment.

2 documents set the numbers on this page. All of them were published in 2026.

We last re-read these sources on . How we verify.

Edited by (Longevity & Research). How pages are checked